Yellow Fever clinical trials
The registry lists 52 studies for Yellow Fever across more than 10 countries. 10 are recruiting or about to start. 39 of them are mainly about Yellow Fever (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Yellow Fever studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Sanofi Pasteur, a Sanofi Company (7) · Singapore General Hospital (4) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (4) · Sanofi (3) · Emory University (2) · Serum Institute of India Pvt. Ltd. (2) · Institute of Tropical Medicine, Belgium (2) · Epicentre (1)
What is being tested here
Drugs under test in Yellow Fever studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Nov 2026A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population · Phase 3 · Sanofi
- Nov 2026Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants · Institute of Tropical Medicine, Belgium
Who these studies take
Of the 7 Yellow Fever studies recruiting now, 1 (14%) set no upper age limit and 6 (86%) stop at 75 or younger. 2 (29%) take children under 18. 1 (14%) are for women only and 0 (0%) for men only; 7 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (14%) | 1 (14%) |
| 18 | 4 (57%) | 3 (43%) |
| 30 | 6 (86%) | 5 (71%) |
| 40 | 6 (86%) | 5 (71%) |
| 50 | 4 (57%) | 3 (43%) |
| 65 | 2 (29%) | 1 (14%) |
| 75 | 2 (29%) | 1 (14%) |
| 85 | 1 (14%) | 0 (0%) |
Across all 52 studies, recruiting or not: 79% stop at 75 or younger and 77% at 65; 35% take children; 2% are for women only and 4% for men only; 90% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 → or search them.
- Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated ParticipantsRecruitingNCT07636551Not applicable1 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)RecruitingNCT06694766Not applicable1 country
- Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D VaccinationRecruitingNCT05859490Phase 1/21 country
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 MonthsNot yet recruitingNCT06815835Phase 31 country
- Characterization of Human Memory Immune Responses to Prior Yellow Fever VaccinationEnrolling by invitationNCT012448021 country
- Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever VaccinationNot yet recruitingNCT05450770Not applicable
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy InfantsRecruitingNCT05447377Phase 32 countries
- Yellow Fever Human Infection Model With YF-17DRecruitingNCT05901454Not applicable1 country
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular ImmunityRecruitingNCT05568953Phase 21 country
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationActive, not recruitingNCT07103148Phase 33 countries
- Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USAActive, not recruitingNCT04942210Phase 21 country
- Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaActive, not recruitingNCT05011123Phase 26 countries
- A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy AdultsCompletedNCT06998004Phase 11 country
- Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever VaccineCompletedNCT05374317Phase 41 country
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy VolunteersCompletedNCT02743455Phase 11 country
- Phase 3 Single Arm, Open Study on vYF in AdultsCompletedNCT07222059Phase 31 country
- Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in AdultsCompletedNCT07002060Phase 31 country
- The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever VaccinationCompletedNCT04269265Phase 1/22 countries
- Human Immune Responses to Yellow Fever VaccinationCompletedNCT00694655Phase 41 country
- Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in AdultsCompletedNCT04142086Phase 11 country
- Trial of an Inactivated Yellow Fever Virus VaccineCompletedNCT05172544Phase 11 country
- A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation (GeKoSkimm-pilot)CompletedNCT06539351Not applicable1 country
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARILCompletedNCT05421611Phase 31 country
- Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever VaccineCompletedNCT01290055Phase 41 country
- Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months OldCompletedNCT03725618Phase 41 country
- Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D VaccinationActive, not recruitingNCT04083430Phase 41 country
- Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in ArgentinaActive, not recruitingNCT05644145Not applicable1 country
- Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral InfectionCompletedNCT04267809Phase 21 country
- Non- Inferiority Fractional-doses Trial for Yellow Fever VaccineCompletedNCT04059471Phase 42 countries
- Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)Active, not recruitingNCT02555072Phase 41 country
- Booster Vaccine for Yellow FeverStatus unknownNCT05332197Phase 3
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompletedNCT01436396Phase 32 countries
- Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever VaccineCompletedNCT01488890Phase 21 country
- Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)CompletedNCT02991495Phase 42 countries
- A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19TerminatedNCT03891420Phase 11 country
- Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRCStatus unknownNCT042353614 countries
- Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary StudyStatus unknownNCT044164771 country
- Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable1 country
- Yellow Fever Vaccine on Statin/ Non Statin SubjectsCompletedNCT03116802Phase 21 country
- Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in HumansCompletedNCT03776786Phase 11 country
- Yellow Fever Vaccine in Patients With Rheumatic DiseasesCompletedNCT03430388Not applicable1 country
- Passive Enhanced Safety Surveillance of Stamaril® Vaccine in KoreaCompletedNCT035416941 country
- The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.CompletedNCT01426243Phase 31 country
- Clinical Study of Immunity Duration of Yellow Fever Vaccine in MilitaryCompletedNCT033382311 country
- Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in ChildrenStatus unknownNCT029901821 country
- Trial of Yellow Fever Inactivated VaccineCompletedNCT00995865Phase 11 country
- The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in HumansCompletedNCT01943305Phase 21 country
- Immunity After Two Doses of Yellow Fever VaccineCompletedNCT025725181 country
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 32 countries